Compare PDEX & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDEX | CGEN |
|---|---|---|
| Founded | 1978 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.1M | 188.2M |
| IPO Year | 1995 | 2001 |
| Metric | PDEX | CGEN |
|---|---|---|
| Price | $51.67 | $2.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $56.00 | $4.00 |
| AVG Volume (30 Days) | 20.7K | ★ 215.9K |
| Earning Date | 04-30-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 345.00 | N/A |
| EPS | ★ 2.07 | N/A |
| Revenue | ★ $66,593,000.00 | N/A |
| Revenue This Year | $7.22 | N/A |
| Revenue Next Year | N/A | $112.37 |
| P/E Ratio | $24.63 | ★ N/A |
| Revenue Growth | ★ 23.68 | N/A |
| 52 Week Low | $23.52 | $1.13 |
| 52 Week High | $70.26 | $2.38 |
| Indicator | PDEX | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 66.58 | 62.49 |
| Support Level | $37.15 | $1.47 |
| Resistance Level | $56.50 | $2.35 |
| Average True Range (ATR) | 2.94 | 0.10 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 91.48 | 77.46 |
Pro-Dex Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers (OEMs) to various countries. Its product portfolio includes autoclavable, battery-powered, electric, and multi-function surgical drivers and shavers used mainly in orthopedic, thoracic, and craniomaxillofacial markets. The company also provides engineering, quality, regulatory consulting services, and manufactures rotary air motors utilized in various industries. Operating out of ISO-certified facilities in California, Pro-Dex serves hospitals, medical labs, and high-tech manufacturers, generating revenue through sales of surgical instruments and related services.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.